Skip to main content

Table 2 Treatments and clinical responses of advanced CRC patients included in the pilot trial

From: Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer

Subject ID First cure
Results of first evaluation
Second cure
Results of second evaluation
Third cure
Results of third evaluation
Survival time (months) at end of study
01a 5-FU + Radiotherapy
Disease progression
8 C FOLFIRI
Disease progression
1 C 5-FU
Disease progression
27
02 4 C FOLFOX
Stable disease
4 C FOLFOX
Stable disease
4 C FOLFOX
Complete response
31
03a 1 C 5-FU
Disease progression
4 C Panitumumab
Disease progression

Disease progression
08
04a 4 C FOLFOX + Bevacizumab
Partial response
4 C FOLFOX + Bevacizumab
Stable disease
4 C Bevacizumab
Disease progression
21
05b 6 C FOLFOX + Bevacizumab
Stable disease
4 C FOLFOX + Bevacizumab
Disease progression
Bevacizumab
Disease progression
25
06b 4 C FOLFIRI + Bevacizumab
Stable disease
4 C FOLFIRI + Bevacizumab
Stable disease
4 C Bevacizumab
Disease progression
24
07 3 C 5-FU
Stable disease
4 C 5-FU
Stable disease
1 C 5-FU
Complete response
24
08 3 C FOLFOX
Stable disease
4 C FOLFOX
Disease progression
4 FOLFIRI
Disease progression
31
09a,b 4 C FOLFOX
Disease progression
4 C FOLFIRI + Bevacizumab
Stable disease
4 C FOLFIRI
Stable disease
14
10 8 C FOLFOX
Stable disease
4 C FOLFOX
Stable disease
N/A
Stable disease
17
11 3 C 5-FU
Stable disease
N/A
Stable disease
N/A
Stable disease
16
12 4 C FOLFIRI + Bevacizumab
Stable disease
4 C FOLFIRI + Bevacizumab
Partial response
4 C Bevacizumab
Stable disease
15
13 3 C 5-FU
Stable disease
2 C 5-FU
Stable disease
2 C 5-FU
Stable disease
15
14 8 C FOLFOX
Stable disease
4 C 5-FU + Folinic acid
Stable disease
N/A
Stable disease
15
15 4 C FOLFOX + Bevacizumab
Partial response
9 C FOLFOX + Bevacizumab
Stable disease
N/A
Partial response
14
16 6 C FOLFOX
Stable disease
4 C FOLFOX
Stable disease
4 C FOLFOX
Stable disease
14
17 7 C FOLFOX + Bevacizumab
Disease progression
5 C FOLFOX + Bevacizumab
Stable disease
N/A
Stable disease
14
18 4 C FOLFOX
Partial response
5 C FOLFOX + Bevacizumab
Partial response
N/A
Partial response
14
19 3 C 5-FU
Stable disease
3 C 5-FU
Stable disease
3 C 5-FU
Disease progression
13
  1. Chemotherapy regimens received by each patient during the course of their treatment, and ensuing clinical outcome (disease progression, stabilization, partial or complete response) determined through three consecutive evaluations. Survival time at completion of study is also provided
  2. aPatient died before end of study as a result of CRC progression
  3. bReceived pre- and or per-surgery chemotherapy